Decision could speed access to LCZ696 for HFrEF patients in the US, reducing total review time from 12 to 8…
Novartis acquires exclusive ex-US rights to Fovista from Ophthotech; upfront payment of USD 200 million plus potential future recruitment and…
Recognition by the US Food and Drug Administration (FDA) that RLX030 has the potential to address a serious unmet medical…